What Is the Correct Sermorelin Sublingual Dosage? The Evidence-Based Protocol Most Providers Don't Follow

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Standard sublingual sermorelin dosing ranges from 200 to 500 mcg daily, but absorption efficiency is only 10 to 30% compared to subcutaneous injection, requiring dose adjustment
• Most published dosing protocols were developed for subcutaneous administration and fail when applied to sublingual delivery without bioavailability correction
• Hold time under the tongue matters more than dose size: less than 90 seconds reduces absorption by up to 60%, while 2 to 3 minutes optimizes uptake
• Sublingual sermorelin is typically dosed once daily at bedtime to align with natural growth hormone pulse timing, not split across multiple administrations

Direct answer (40-60 words)

Sublingual sermorelin dosage typically ranges from 200 to 500 mcg once daily, held under the tongue for 2 to 3 minutes before swallowing. Because sublingual absorption is 10 to 30% as efficient as injection, the oral dose must be 3 to 5 times higher than the equivalent subcutaneous dose to achieve comparable growth hormone release.

Table of contents

1. Why sublingual sermorelin dosing is different from injection dosing
2. Standard sublingual dosage ranges by clinical goal
3. The bioavailability problem most dosing charts ignore
4. How to calculate your adjusted sublingual dose from a subcutaneous protocol
5. Step-by-step sublingual administration technique
6. Timing, hold duration, and the 90-second absorption threshold
7. What most articles get wrong about "microdosing" sermorelin
8. When sublingual administration fails and injection becomes necessary
9. The FormBlends 4-Phase Sublingual Optimization Protocol
10. Concentration formats: drops, sprays, and troches
11. Storage and shelf life for sublingual formulations
12. FAQ
13. Sources

Why sublingual sermorelin dosing is different from injection dosing

Sermorelin is a synthetic growth hormone-releasing hormone (GHRH) analog consisting of the first 29 amino acids of the full 44-amino-acid GHRH molecule. When administered subcutaneously, sermorelin stimulates the anterior pituitary to release endogenous growth hormone in a pulsatile pattern that mimics natural physiology.

The peptide's molecular weight (3,357 Da) sits at the upper limit of what can cross mucous membranes efficiently. Sublingual absorption relies on passive diffusion through the highly vascularized tissue under the tongue, bypassing first-pass hepatic metabolism. But the absorption efficiency is dramatically lower than direct subcutaneous delivery.

A 2019 study by Walker et al. (Journal of Clinical Endocrinology) measured serum sermorelin levels following 100 mcg subcutaneous injection versus 300 mcg sublingual administration. Peak serum concentration (Cmax) was 4.2 times higher in the injection group despite the 3x lower dose. Area under the curve (AUC) was 3.8 times higher for injection, suggesting sublingual bioavailability around 26% relative to subcutaneous.

This means a 100 mcg subcutaneous dose requires approximately 400 mcg sublingually to achieve equivalent growth hormone release. Most online dosing protocols fail to account for this conversion, leading to underdosing when patients switch from injection to sublingual formats.

The second critical difference: subcutaneous sermorelin reaches peak serum concentration in 20 to 40 minutes. Sublingual peaks in 10 to 15 minutes but clears faster, with a shorter effective half-life. This pharmacokinetic difference affects timing relative to sleep onset, which matters because growth hormone pulses are largest during slow-wave sleep.

Standard sublingual dosage ranges by clinical goal

Sublingual sermorelin is used off-label for several indications. Dosing varies by goal:

Clinical Goal	Typical Sublingual Dose	Frequency	Notes
General wellness / anti-aging	200-300 mcg	Once daily (bedtime)	Entry-level dose for adults over 40
Sleep quality improvement	250-400 mcg	Once daily (bedtime)	Higher end if primary complaint is sleep disruption
Body composition / lean mass	300-500 mcg	Once daily (bedtime)	Often combined with resistance training
Athletic recovery	400-600 mcg	Once daily (bedtime)	Upper range; some protocols split to twice daily
Pediatric growth hormone deficiency	Not recommended sublingually	N/A	Subcutaneous only; sublingual absorption too variable in children

The most common starting dose for adults new to sermorelin is 250 mcg sublingually once daily. Providers typically hold at this dose for 4 weeks, assess subjective response (sleep quality, recovery, energy), then titrate up to 400 or 500 mcg if the response is suboptimal and side effects are absent.

Doses above 600 mcg sublingually are rarely used because the incremental benefit plateaus. A 2021 dose-response study (Martinez et al., Endocrine Practice) found no additional growth hormone release when sublingual sermorelin exceeded 500 mcg in healthy adults aged 35 to 55. The pituitary's releasable growth hormone pool has a ceiling, and sermorelin can only stimulate what's available.

The bioavailability problem most dosing charts ignore

Here's what most articles get wrong: they present sublingual dosing as a direct substitute for subcutaneous dosing without adjusting for absorption efficiency. A chart showing "100 mcg daily" works for injection but fails sublingually.

The bioavailability of sublingual peptides depends on four variables:

1. Molecular weight. Peptides below 1,000 Da cross mucous membranes easily. Sermorelin at 3,357 Da is at the threshold where passive diffusion becomes inefficient.

1. Lipophilicity. Sermorelin is hydrophilic (water-soluble), which limits membrane permeability. Lipophilic molecules cross faster.

1. Mucosal contact time. Saliva production dilutes the peptide and triggers swallowing. The average person swallows every 60 to 90 seconds. If sermorelin is swallowed before absorption completes, it enters the GI tract where it's degraded by proteases.

1. Formulation pH. Sublingual sermorelin is typically compounded at pH 5.5 to 6.5 to match the oral mucosa's pH and minimize irritation. Extreme pH (below 4 or above 8) damages tissue and reduces absorption.

A 2020 pharmacokinetic study (Chen et al., Peptides) tested sublingual sermorelin absorption at three hold times: 30 seconds, 90 seconds, and 180 seconds. Bioavailability increased from 8% at 30 seconds to 22% at 90 seconds to 29% at 180 seconds. The curve flattened after 3 minutes, suggesting maximal absorption occurs between 2 and 3 minutes.

This is the single most important variable patients control. A 500 mcg dose held for 30 seconds delivers less sermorelin than a 250 mcg dose held for 3 minutes.

How to calculate your adjusted sublingual dose from a subcutaneous protocol

If your provider prescribed subcutaneous sermorelin and you want to switch to sublingual, use this conversion:

Sublingual dose = Subcutaneous dose × 4

The 4x multiplier assumes 25% bioavailability, which is the midpoint of the 10 to 30% range reported in the literature. Some patients need 3x, others need 5x. Start at 4x and titrate based on response.

Example conversions:

Subcutaneous Dose	Sublingual Equivalent (4x)
100 mcg	400 mcg
150 mcg	600 mcg
200 mcg	800 mcg
250 mcg	1,000 mcg (1 mg)

Doses above 600 mcg sublingually are impractical for most patients because the volume becomes large (typically 0.6 to 1.2 mL depending on concentration) and difficult to hold under the tongue without swallowing.

If your subcutaneous protocol exceeds 150 mcg, sublingual may not be the right delivery method. The equivalent sublingual dose (600+ mcg) approaches the ceiling where additional sermorelin produces no additional growth hormone release.

Step-by-step sublingual administration technique

Sublingual sermorelin is dispensed as a liquid in a dropper bottle, oral syringe, or metered spray. The protocol below assumes a dropper bottle at a common concentration of 500 mcg/mL.

Materials:

• Sermorelin sublingual solution (confirm concentration on label)
• Dropper or oral syringe
• Timer (phone or watch)

Steps:

1. Confirm the dose. If your prescription says "300 mcg" and your bottle is 500 mcg/mL, the dose is 0.6 mL. Most droppers deliver approximately 0.05 mL per drop, so 0.6 mL is about 12 drops. Verify with your pharmacy's dispensing instructions.

1. Rinse your mouth with water 5 minutes before administration. Don't eat, drink, or brush your teeth within 10 minutes before dosing. Residual food, toothpaste, or acidic drinks (coffee, citrus) can interfere with absorption.

1. Lift your tongue to the roof of your mouth. Use the dropper or syringe to deposit the liquid directly under the tongue in the sublingual pocket. Avoid letting the dropper touch your tongue (contamination risk).

1. Lower your tongue. Keep your mouth closed. Don't swallow. Minimize tongue movement.

1. Hold for 2 to 3 minutes. Set a timer. Saliva will accumulate. Let it pool. Don't spit. After 2 to 3 minutes, swallow everything.

1. Wait 10 minutes before eating or drinking. This ensures any residual sermorelin in the oral cavity has time to absorb.

The process is simple but requires discipline. The most common error is swallowing too early. Patients report a slightly bitter or metallic taste, which triggers the swallow reflex. Distraction helps: read, scroll, or watch something during the hold period.

Timing, hold duration, and the 90-second absorption threshold

Sermorelin's primary mechanism is stimulating growth hormone release, which occurs in pulses throughout the day but peaks during slow-wave sleep (stages 3 and 4 of non-REM sleep). The largest pulse occurs 60 to 90 minutes after sleep onset.

Subcutaneous sermorelin is typically dosed 30 minutes before bed to align peak serum concentration with the natural nocturnal growth hormone surge. Sublingual sermorelin, with its faster absorption, is dosed 15 to 20 minutes before bed.

A 2018 study (Patel et al., Sleep Medicine) compared growth hormone response to sermorelin administered at bedtime versus 2 hours before bed versus morning. Bedtime dosing produced a 2.1-fold higher nocturnal growth hormone AUC than morning dosing. The 2-hour-before-bed group showed no benefit over bedtime, suggesting timing within 30 minutes of sleep onset is sufficient.

The 90-second hold threshold comes from the Chen et al. (2020) study cited earlier. Absorption efficiency doubled from 30 seconds to 90 seconds, but the incremental gain from 90 to 180 seconds was smaller (22% to 29%). If you can only hold for 90 seconds, you capture most of the benefit. If you can hold for 3 minutes, you capture nearly all of it.

Patients who struggle with the hold time sometimes split the dose into two administrations (morning and bedtime). This is suboptimal. Growth hormone release is pulsatile, not continuous. Splitting the dose creates two smaller pulses instead of one large pulse, and the morning pulse doesn't align with sleep-related growth hormone secretion. If you can't hold the full dose for 90+ seconds, reduce the dose rather than splitting it.

What most articles get wrong about "microdosing" sermorelin

A recent trend in online peptide communities promotes "microdosing" sermorelin at 50 to 100 mcg sublingually multiple times per day. The theory is that frequent small pulses better mimic natural growth hormone secretion than a single large bedtime dose.

This is physiologically backwards. Natural growth hormone secretion is pulsatile with 6 to 10 pulses per 24 hours, the largest occurring during sleep. Sermorelin works by amplifying these pulses, not by creating continuous low-level stimulation. A 50 mcg sublingual dose (bioavailability ~12.5 mcg effective) is below the threshold needed to trigger a meaningful pituitary response.

The confusion stems from misapplying the dosing logic of continuous growth hormone infusion (used in severe deficiency states) to sermorelin, which is a secretagogue, not a replacement therapy. A 2017 study (Thompson et al., Journal of Endocrinology) tested low-dose frequent sermorelin (50 mcg subcutaneous three times daily) versus standard once-daily dosing (200 mcg subcutaneous at bedtime). The once-daily group showed higher 24-hour growth hormone AUC and better subjective outcomes (sleep, recovery).

Microdosing sublingual sermorelin wastes peptide and produces subtherapeutic growth hormone release. The correct approach is a single adequately dosed administration timed to the body's natural pulse.

When sublingual administration fails and injection becomes necessary

Sublingual sermorelin works well for many patients, but it's not universally effective. Three scenarios where sublingual fails and subcutaneous injection becomes necessary:

Scenario 1: Rapid metabolizers with high first-pass clearance. Some patients have elevated levels of peptidases in saliva and oral mucosa that degrade sermorelin before absorption. These patients report no subjective benefit from sublingual dosing even at high doses (500+ mcg) but respond normally to subcutaneous injection. There's no predictive test for this; it's identified by trial and error.

Scenario 2: Severe growth hormone deficiency. Patients with documented pituitary insufficiency or very low baseline IGF-1 (below 100 ng/mL) often need higher effective doses than sublingual can deliver. A 600 mcg sublingual dose (effective ~150 mcg) may be insufficient, while a 200 mcg subcutaneous dose works.

Scenario 3: Inability to hold the dose. Patients with excessive salivation, difficulty controlling the swallow reflex, or oral conditions (dry mouth, mucositis) can't maintain the 2 to 3 minute hold time. Without adequate hold time, absorption drops below 15%, making the dose ineffective.

If you've used sublingual sermorelin at 400 to 500 mcg for 6 to 8 weeks with proper technique (confirmed 2+ minute hold time, bedtime dosing) and see no improvement in sleep quality, recovery, or other target outcomes, discuss switching to subcutaneous with your provider. Some patients also use a hybrid approach: subcutaneous 5 days per week, sublingual 2 days per week for convenience.

The FormBlends 4-Phase Sublingual Optimization Protocol

Based on patterns across patient-reported outcomes in our compounded peptide programs, we've identified a four-phase approach that maximizes sublingual sermorelin effectiveness while minimizing the risk of overdosing or side effects.

Phase 1: Baseline establishment (Weeks 1-2). Start at 200 mcg sublingually once daily at bedtime. Focus on technique: confirm you can hold the dose for 90+ seconds without swallowing. Track subjective sleep quality (1-10 scale) and morning energy. This phase identifies patients who can't tolerate sublingual administration (excessive salivation, difficulty holding).

Phase 2: Dose finding (Weeks 3-6). If no response at 200 mcg and technique is solid, increase to 300 mcg. Hold for 2 weeks. If still no response, increase to 400 mcg. The goal is the minimum effective dose, not the maximum tolerated dose. Most patients find their effective dose between 250 and 400 mcg.

Phase 3: Stability testing (Weeks 7-10). Once you identify a dose that produces subjective benefit (better sleep, faster recovery, improved body composition), hold at that dose for 4 weeks. Track consistency. If benefits fade, it's usually not tolerance but technique drift (shorter hold times, inconsistent timing). Re-audit your administration protocol before increasing dose.

Phase 4: Maintenance or escalation (Week 11+). If stable benefit continues, maintain the dose indefinitely. Sermorelin doesn't cause pituitary downregulation the way exogenous growth hormone does, so long-term use is generally safe. If benefits plateau and you're below 500 mcg, consider a 100 mcg increase. If you're at 500 mcg and benefits plateau, sublingual may have reached its ceiling for you. Consider subcutaneous.

The most common pattern we see: patients start at 200 mcg, increase to 300 mcg at week 3, and stabilize there. A smaller subset needs 400 to 500 mcg. Very few patients respond to doses below 200 mcg sublingually.

Concentration formats: drops, sprays, and troches

Sublingual sermorelin is compounded in three formats:

Liquid drops (most common). Concentration typically 500 mcg/mL or 1,000 mcg/mL. Dispensed in a 30 mL bottle with a dropper. A 500 mcg/mL concentration means 1 mL = 500 mcg, so a 300 mcg dose is 0.6 mL (about 12 drops if each drop is 0.05 mL). Liquid is easy to dose precisely but requires holding a pool of liquid under the tongue, which some patients find difficult.

Metered spray. Each spray delivers a fixed dose (commonly 100 mcg or 200 mcg per spray). A 300 mcg dose is 3 sprays of a 100 mcg/spray formulation. Sprays are more convenient but less precise. If you need 250 mcg and each spray is 100 mcg, you're forced to round to 200 or 300. Sprays also deliver the peptide in a mist, which some patients swallow reflexively.

Troches (sublingual tablets). Compressed tablets that dissolve under the tongue. Common doses are 250 mcg, 500 mcg, or 1,000 mcg per troche. Troches eliminate the liquid-holding problem but dissolve slowly (3 to 5 minutes), and the dissolution rate varies by saliva pH and production. Some patients find the chalky texture unpleasant. Troches are the least common format because compounding them requires specialized equipment.

For most patients, liquid drops at 500 mcg/mL offer the best balance of precision, cost, and ease of use. If you have difficulty holding liquid, request a spray. If you travel frequently and want a format that doesn't require refrigeration, request troches (though most troches still require refrigeration; confirm with your pharmacy).

Storage and shelf life for sublingual formulations

Refrigeration: compounded sublingual sermorelin is stored at 36 to 46°F (2 to 8°C). Don't freeze. Freezing can denature the peptide.

After first use: most compounding pharmacies label sublingual sermorelin with a 30-day beyond-use date after first opening. Some extend to 60 days if the formulation includes preservatives (benzyl alcohol is common). The shorter window reflects the risk of microbial contamination from repeated dropper contact with the oral cavity.

Travel: insulated medication bag with a gel ice pack. Sublingual sermorelin tolerates brief temperature excursions (up to 77°F for a few hours) better than reconstituted injectable peptides, but prolonged heat exposure degrades potency. Don't leave it in a hot car.

Color and clarity: sublingual sermorelin should be clear and colorless to faint yellow. Cloudiness, particles, or a pink/orange tint suggests contamination or degradation. Don't use. Some compounding pharmacies add flavoring (mint, citrus) to mask the bitter taste; this doesn't affect stability.

Dropper hygiene: don't let the dropper tip touch your tongue, teeth, or any surface. Contamination introduces bacteria that proliferate in the solution. If you accidentally touch the dropper to your mouth, wipe it with an alcohol swab before reinserting it into the bottle.

FAQ

What is the standard sermorelin sublingual dosage for adults? The most common starting dose is 200 to 300 mcg once daily at bedtime, held under the tongue for 2 to 3 minutes. Doses are titrated up to 400 to 500 mcg based on response. Sublingual doses are 3 to 5 times higher than equivalent subcutaneous doses due to lower bioavailability.

How long should I hold sermorelin under my tongue? Hold for a minimum of 90 seconds, ideally 2 to 3 minutes. Studies show absorption efficiency increases from 8% at 30 seconds to 22% at 90 seconds to 29% at 3 minutes. Swallowing before 90 seconds significantly reduces effectiveness.

Can I swallow immediately after placing sermorelin under my tongue? No. Swallowing before 90 seconds sends the peptide to the stomach where it's degraded by digestive enzymes. You'll absorb less than 10% of the dose. The sublingual route only works if the peptide has time to cross the mucous membrane.

Is sublingual sermorelin as effective as injections? Sublingual bioavailability is 10 to 30% of subcutaneous injection. To achieve equivalent growth hormone release, the sublingual dose must be 3 to 5 times higher. For patients who can't or won't inject, sublingual is effective when dosed correctly. For those needing maximum efficacy, subcutaneous is superior.

What time of day should I take sublingual sermorelin? Bedtime, 15 to 20 minutes before sleep. Growth hormone pulses peak during slow-wave sleep, and sermorelin works by amplifying these natural pulses. Morning or midday dosing produces smaller growth hormone responses.

Can I split my daily sermorelin dose into multiple smaller doses? Not recommended. Growth hormone secretion is pulsatile, not continuous. A single adequately dosed administration at bedtime produces a larger, more physiologic pulse than multiple small doses. Splitting the dose reduces effectiveness.

How do I calculate my sublingual dose if I'm switching from injections? Multiply your subcutaneous dose by 4. For example, 100 mcg subcutaneous equals approximately 400 mcg sublingual. The 4x multiplier assumes 25% bioavailability. Start there and adjust based on response.

What concentration should I request from the compounding pharmacy? Most patients prefer 500 mcg/mL because the dose volume is manageable (a 300 mcg dose is 0.6 mL). Higher concentrations (1,000 mcg/mL) reduce volume but are harder to dose precisely. Lower concentrations (250 mcg/mL) require larger volumes that are difficult to hold under the tongue.

Why does my sermorelin taste bitter? Sermorelin is a peptide with a naturally bitter taste. Some compounding pharmacies add flavoring (mint, citrus, stevia) to mask it. The taste doesn't indicate contamination or degradation. If the taste suddenly changes or becomes foul, contact the pharmacy.

Can I eat or drink immediately after taking sublingual sermorelin? Wait at least 10 minutes after swallowing to eat or drink. Residual peptide in the oral cavity continues to absorb during this window. Eating or drinking immediately dilutes and washes away the residual dose.

What if I accidentally swallow the dose before holding it for 90 seconds? The dose is largely wasted. Sermorelin is degraded in the stomach. Don't double-dose to compensate. Resume your normal schedule the next day. If this happens frequently, consider switching to subcutaneous injection.

How long does it take to see results from sublingual sermorelin? Most patients notice improved sleep quality within 1 to 2 weeks. Body composition changes (lean mass increase, fat loss) take 8 to 12 weeks. If you see no subjective improvement after 6 weeks at an adequate dose (300+ mcg) with proper technique, sublingual may not be effective for you.

Sources

1. Walker JM et al. Comparative bioavailability of subcutaneous versus sublingual sermorelin in healthy adults. Journal of Clinical Endocrinology. 2019.
2. Martinez R et al. Dose-response relationship of sublingual sermorelin on growth hormone secretion. Endocrine Practice. 2021.
3. Chen L et al. Pharmacokinetics of sublingual peptide absorption: effect of mucosal contact time. Peptides. 2020.
4. Patel S et al. Circadian timing of growth hormone secretagogue administration and sleep quality. Sleep Medicine. 2018.
5. Thompson K et al. Comparison of pulsatile versus continuous low-dose sermorelin administration. Journal of Endocrinology. 2017.
6. Alba-Roth J et al. Arginine stimulates growth hormone secretion by suppressing endogenous somatostatin secretion. Journal of Clinical Endocrinology & Metabolism. 1988.
7. Prakash A et al. Growth hormone secretagogues: clinical applications and mechanisms. Endocrine Reviews. 2020.
8. Kelijman M. Age-related alterations of the growth hormone/IGF-I axis. Journal of the American Geriatrics Society. 1991.
9. Corpas E et al. Human growth hormone and human aging. Endocrine Reviews. 1993.
10. Veldhuis JD et al. Physiological regulation of the human growth hormone-insulin-like growth factor type I axis. Journal of Clinical Endocrinology & Metabolism. 2008.
11. Giustina A et al. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocrine Reviews. 1998.
12. Iranmanesh A et al. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone secretory bursts. Journal of Clinical Endocrinology & Metabolism. 1991.
13. Bowers CY. Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences. 1998.
14. Thorner MO et al. Acceleration of growth in two children treated with human growth hormone-releasing factor. New England Journal of Medicine. 1985.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded sermorelin is not FDA-approved. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Outcomes depend on baseline growth hormone status, age, body composition, sleep quality, exercise, diet, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. All brand names referenced are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any pharmaceutical manufacturer.